migraine. Migraine, unspecified
Conditions
Interventions
Intervention 1: Intervention group: Supplementation of zinc sulfate (220 mg including 50 mg of elemental zinc, Alhavi Company), every day 1 supplement, 8 weeks. Intervention 2: control group: placebo
Treatment - Drugs
Placebo
Intervention group: Supplementation of zinc sulfate (220 mg including 50 mg of elemental zinc, Alhavi Company), every day 1 supplement, 8 weeks
control group: placebo (made at the School of Pharmacy, Isfahan University of Medical Sciences ), every day 1 supplement, 8 weeks
Sponsors
Vice chancellor for research, University of Medical Sciences of Esfahan
Eligibility
Sex/Gender
All
Age
20 Years to 60 Years
Inclusion criteria
Inclusion criteria: aged 20-60 years; confirmation of migraine by neurologist; desire to participate in present study; do not use of oral contraceptive pill, lack of tension headaches.
Exclusion criteria
Exclusion criteria: having chronic medical diseases; use of supplements containing Zn, vitamin E, vitamin C, Selenium and Beta-carotene
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Migraine symptoms ( severity, frequency and average duration of migraine attacks). Timepoint: At first and end of intervention. Method of measurement: Questionaire.;C-reactive protein (CRP). Timepoint: At first and end of intervention. Method of measurement: Laboratory analysis ( blood test). | — |
Secondary
| Measure | Time frame |
|---|---|
| Migraine Disability Assessment. Timepoint: At first and end of intervention. Method of measurement: Questionaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHedieh Ahmadi
Esfahan University of Medical Sciences
Outcome results
None listed